BiotechTube

Olaparib + Bevacizumab

ApprovedActive
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Carcinoma, Ovarian Epithelial

Conditions

Carcinoma, Ovarian Epithelial

Trial Timeline

Sep 15, 2023 → Sep 15, 2027

NCT ID
NCT06121401

About Olaparib + Bevacizumab

Olaparib + Bevacizumab is a approved stage product being developed by AstraZeneca for Carcinoma, Ovarian Epithelial. The current trial status is active. This product is registered under clinical trial identifier NCT06121401. Target conditions include Carcinoma, Ovarian Epithelial.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Ovarian Epithelial were approved

Approved (20) Terminated (2) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅GefitinibAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06121401ApprovedActive

Competing Products

20 competing products in Carcinoma, Ovarian Epithelial

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35